136 related articles for article (PubMed ID: 38503480)
1. Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment.
Fiorino G; Bent-Ennakhil N; Varriale P; Braegger F; Hoefkens E
Inflamm Bowel Dis; 2024 Mar; ():. PubMed ID: 38503480
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory Bowel Disease Patients' Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT Study.
Schubert S; Picker N; Cavlar T; Knop J; Kahraman A; Mohl W
Adv Ther; 2022 Jun; 39(6):2889-2905. PubMed ID: 35451740
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
[TBL] [Abstract][Full Text] [Related]
4. Patients with Inflammatory Bowel Disease Have Heterogeneous Treatment Preferences That Are Largely Determined by the Avoidance of Abdominal Pain and Side Effects [P-POWER IBD Study].
Louis E; Siegel CA; James B; Heidenreich S; Krucien N; Ghosh S
J Crohns Colitis; 2023 Mar; 17(2):231-239. PubMed ID: 36130188
[TBL] [Abstract][Full Text] [Related]
5. Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment.
Hazlewood GS; Pokharel G; Deardon R; Marshall DA; Bombardier C; Tomlinson G; Ma C; Seow CH; Panaccione R; Kaplan GG
PLoS One; 2020; 15(1):e0227635. PubMed ID: 31945089
[TBL] [Abstract][Full Text] [Related]
6. Patient and physician preferences for ulcerative colitis treatments in the United States.
Boeri M; Myers K; Ervin C; Marren A; DiBonaventura M; Cappelleri JC; Hauber B; Rubin DT
Clin Exp Gastroenterol; 2019; 12():263-278. PubMed ID: 31354328
[No Abstract] [Full Text] [Related]
7. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
[TBL] [Abstract][Full Text] [Related]
8. How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients.
Brunet-Houdard S; Monmousseau F; Berthon G; Des Garets V; Laharie D; Picon L; Fotsing G; Gargot D; Charpentier C; Buisson A; Trang-Poisson C; Dib N; Rusch E; Aubourg A;
Scand J Gastroenterol; 2022 Nov; 57(11):1312-1320. PubMed ID: 35722732
[TBL] [Abstract][Full Text] [Related]
9. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.
Hodgkins P; Swinburn P; Solomon D; Yen L; Dewilde S; Lloyd A
Patient; 2012; 5(1):33-44. PubMed ID: 22077619
[TBL] [Abstract][Full Text] [Related]
10. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.
Mühlbacher AC; Nübling M
Eur J Health Econ; 2011 Jun; 12(3):193-203. PubMed ID: 20107856
[TBL] [Abstract][Full Text] [Related]
11. Patients Prioritize a Low-volume Bowel Preparation in Colitis-associated Colorectal Cancer Surveillance: A Discrete Choice Experiment.
Wijnands AM; Te Groen M; Peters Y; Kaptein AA; Oldenburg B; Hoentjen F; Lutgens MWMD
Inflamm Bowel Dis; 2022 Jul; 28(7):1053-1060. PubMed ID: 34487155
[TBL] [Abstract][Full Text] [Related]
12. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management.
Johnson FR; Hauber B; Özdemir S; Siegel CA; Hass S; Sands BE
J Manag Care Pharm; 2010 Oct; 16(8):616-28. PubMed ID: 20866166
[TBL] [Abstract][Full Text] [Related]
13. Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe.
Willems D; Hinzpeter EL; Van der Zee HH; Sayed CJ; Ingram JR; Beaudart C; Evers SMAA; Hiligsmann M
Patient; 2023 Mar; 16(2):153-164. PubMed ID: 36630078
[TBL] [Abstract][Full Text] [Related]
14. What matters most to patients with multiple myeloma? A Pan-European patient preference study.
Janssens R; Lang T; Vallejo A; Galinsky J; Morgan K; Plate A; De Ronne C; Verschueren M; Schoefs E; Vanhellemont A; Delforge M; Schjesvold F; Cabezudo E; Vandebroek M; Stevens H; Simoens S; Huys I
Front Oncol; 2022; 12():1027353. PubMed ID: 36523996
[TBL] [Abstract][Full Text] [Related]
15. A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective.
Louis E; Ramos-Goñi JM; Cuervo J; Kopylov U; Barreiro-de Acosta M; McCartney S; Rosenfeld G; Bettenworth D; Hart A; Novak K; Donnet X; Easton D; Saldaña R; Protze K; Tzur E; Alperovich G; Casellas F
Patient; 2020 Jun; 13(3):317-325. PubMed ID: 31997116
[TBL] [Abstract][Full Text] [Related]
16. Patients' Preferences for Artificial Intelligence Applications Versus Clinicians in Disease Diagnosis During the SARS-CoV-2 Pandemic in China: Discrete Choice Experiment.
Liu T; Tsang W; Huang F; Lau OY; Chen Y; Sheng J; Guo Y; Akinwunmi B; Zhang CJ; Ming WK
J Med Internet Res; 2021 Feb; 23(2):e22841. PubMed ID: 33493130
[TBL] [Abstract][Full Text] [Related]
17. Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations.
Le Berre C; Loy L; Lönnfors S; Avedano L; Piovani D
World J Gastroenterol; 2020 Aug; 26(29):4343-4355. PubMed ID: 32848338
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous Patient Preferences for Modern Antiretroviral Therapy: Results of a Discrete Choice Experiment.
Ostermann J; Mühlbacher A; Brown DS; Regier DA; Hobbie A; Weinhold A; Alshareef N; Derrick C; Thielman NM
Value Health; 2020 Jul; 23(7):851-861. PubMed ID: 32762986
[TBL] [Abstract][Full Text] [Related]
19. Understanding patients' preferences for osteoporosis treatment: the impact of patients' characteristics on subgroups and latent classes.
Cornelissen D; Boonen A; Bours S; Evers S; Dirksen C; Hiligsmann M
Osteoporos Int; 2020 Jan; 31(1):85-96. PubMed ID: 31606825
[TBL] [Abstract][Full Text] [Related]
20. Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis.
Stamuli E; Corry S; Foss P
Int J Technol Assess Health Care; 2023 Apr; 39(1):e21. PubMed ID: 37074007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
